Envestnet identifies compounds from EVM301 Series for preclinical development

Enveric Biosciences announced that it has identified three novel compounds from its EVM301 Series with the potential to offer a first-in-class approach to address difficult-to-treat disorders by promoting neuroplasticity without inducing hallucinations. Enveric plans to select one of the compounds for preclinical development early in 2024 in anticipation of Investigational New Drug IND application for a first-in-human clinical trial…”Our industry leading drug-design team has progressed Enveric’s EVM301 Series of compounds significantly closer to the nomination of a lead candidate for preclinical and subsequent clinical development,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “The pharmacologic profiles of the identified three candidate compounds provide evidence that our design and screening processes have discovered and isolated promising candidates with the potential to offer significantly improved treatments for severe and undertreated mental health disorders, which have seen little innovation for decades. We are committed to aggressively pursuing a thorough and expedited preclinical program in 2024 in preparation for an IND application.”